Related Experiment Video
Updated: Aug 30, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Stages of HIV replication and targets for therapeutic intervention
1Department of Biochemistry and Molecular Biology, Faculty of Medicine, Debrecen University, H-4012 Debrecen, Hungary. tozser@indi.biochem.dote.hu
The replication cycle of human immunodeficiency virus (HIV) is divided into an early and a late phase. Most of the steps of the cycle have been targeted in antiviral therapy, although the drugs currently available for clinical use are only effective against two replication enzymes of the virus, either against the reverse transcriptase or against the viral protease. The introduction of combination anti-retroviral therapy changed the prognosis of HIV infection. HIV-related morbidity and mortality rates in patients with advanced HIV infection have significantly declined. However, there are severe limits of HAART. Current anti-retroviral therapy do not allow viral eradication, therefore long-term use of the drugs is required. As a consequence, resistance develops in a significant portion of patients. Furthermore, several adverse metabolic side effects have been observed associated with the therapy. Therefore new approaches are required to control or eradicate this deadly virus infection.
The replication cycle of human immunodeficiency virus (HIV) is divided into an early and a late phase. Most of the steps of the cycle have been targeted in antiviral therapy, although the drugs currently available for clinical use are only effective against two replication enzymes of the virus, either against the reverse transcriptase or against the viral protease. The introduction of combination anti-retroviral therapy changed the prognosis of HIV infection. HIV-related morbidity and mortality rates in patients with advanced HIV infection have significantly declined. However, there are severe limits of HAART. Current anti-retroviral therapy do not allow viral eradication, therefore long-term use of the drugs is required. As a consequence, resistance develops in a significant portion of patients. Furthermore, several adverse metabolic side effects have been observed associated with the therapy. Therefore new approaches are required to control or eradicate this deadly virus infection.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Size and Structure of Viral Genomes
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release

